Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5949
    +0.0012 (+0.21%)
     
  • NZD/EUR

    0.5548
    +0.0002 (+0.04%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.96
    +0.15 (+0.18%)
     
  • GOLD

    2,330.80
    -7.60 (-0.33%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,040.38
    -4.43 (-0.06%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,219.81
    +18.54 (+0.11%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • NZD/JPY

    92.5730
    +0.4580 (+0.50%)
     

Tresiba Emerged as a Blockbuster Therapy in 2017

Tresiba Emerged as a Blockbuster Therapy in 2017

In 2017, Novo Nordisk’s (NVO) basal insulin therapy, Tresiba, reported revenue of nearly 7.3 billion Danish kroner and attained blockbuster status. The drug has witnessed rapid uptake in markets in which it has par access compared to competing products, such as insulin glargine U100. In the United States, Novo Nordisk managed to attain a 34% share of the total basal insulin market by volume as of January 2018.